LILIAN ORUMANA: Open Payments
NPI 1457058091 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,497 in 124 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $1,237 · 2025 $2,497
Food & beverage: $2,497
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $356 |
| ABBVIE INC. | 24 | $289 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $269 |
| E.R. Squibb & Sons, L.L.C. | 9 | $237 |
| Lundbeck LLC | 8 | $199 |
| Biogen, Inc. | 9 | $194 |
| Alkermes, Inc. | 7 | $193 |
| Teva Pharmaceuticals USA, Inc. | 10 | $153 |
| Almatica Pharma LLC | 6 | $137 |
| Collegium Pharmaceutical, Inc. | 5 | $105 |
Products named: FANAPT, VRAYLAR, REXULTI, CAPLYTA, COBENFY, ZURZUVAE, ARISTADA, LOREEV XR.
Industry payments across AZ — which companies pay providers there.
